About TadHealth TadHealth is a purpose-built, advanced electronic health record platform designed specifically for K-12 schools. Created in collaboration with educators and mental health experts, ...

Attending the events surrounding the J.P. Morgan Healthcare Conference in San Francisco is a great opportunity for Cadrenal Therapeutics to engage directly with current and prospective partners and ...

Population Health Partners and dacadoo Announce Strategic Partnership “We are working with dacadoo because they are leaders in their field of health engagement with a scalable digital solution. ” said ...

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell ...

ORANGE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...

The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity. The study will ...

Lifeward selected Verita as its partner in these targeted regions to integrate ReWalk into their multi-modal treatment methodologies for people living with neurological and spinal cord injuries. Today ...

About Avalyn Pharma Avalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver ...

Alira Health, a global advisory firm and CRO, today announced the appointment of Dr. Susanne Schaffert as Senior Advisor and Patient-Centric Ambassador. Dr. Schaffert is a highly respected ...

“The results of this first-in-child trial show some encouraging signals of activity in a highly aggressive chemotherapy resistant brain cancer, such as partial tumor response in a diffuse intrinsic ...

A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation ...

Based on these data, SAB BIO has advanced SAB-142 into a registrational Phase 2b trial SAFEGUARD to evaluate SAB-142 in adult and pediatric patients with new-onset, stage 3 T1D. The SAFEGUARD trial is ...